Mammotome and Sirius Medical Expand Partnership for Distribution of the Pintuition® System Across Italy and Poland
September 24, 2025
Quickborn, Germany and Eindhoven, Netherlands – September 24, 2025 - Mammotome, a globally recognized leader in breast care, and Sirius Medical, a pioneer of Surgical Marker Navigation, are proud to announce an exclusive distribution agreement for the Pintuition® System in Italy and Poland. Building on the successful collaboration in the United States and Germany initiated earlier this year, Mammotome and Sirius Medical are further strengthening their partnership through this expanded commitment.
Breast cancer continues to pose a major global health challenge, underscoring the critical need for advanced technologies that enhance patient outcomes and optimize surgical procedures. The Sirius Pintuition® System marks a notable innovation in breast cancer surgery, empowering surgeons with greater precision and efficiency by replacing conventional localization techniques with Surgical Marker Navigation for accurate tumor removal.
“The success we have achieved together in Germany and the United States demonstrates the strength of our partnership,” said Jan Willem Beijer, Chief Commercial Officer of Sirius Medical. “We are excited to bring these advanced solutions to even more markets, supporting healthcare providers and improving patient care on a larger scale.”
As a leading innovator in breast cancer diagnostics and surgical solutions, Mammotome is uniquely positioned to commercialize the Pintuition® System. Backed by a deep understanding of the needs of breast care professionals and their patients, Mammotome will leverage its well-established sales network across Italy and Poland to ensure seamless access to Sirius Medical’s state-of-the-art technology.
“Our collaboration with Sirius Medical is built on mutual trust and a shared vision,” said Olaf Andrich, General Manager of EMEA and APAC for Mammotome. “Expanding distribution to these new countries is a natural next step that underscores our joint dedication to innovation and excellence in healthcare.”
This collaboration also enables healthcare providers and surgeons to benefit from Mammotome’s comprehensive portfolio of premium breast care products, including the Neoprobe® Gamma Detection System and the HydroMARK™ Breast Biopsy Site Marker. Together, these technologies provide clinicians with a comprehensive suite of premium solutions designed to meet the evolving needs of breast surgery.
About Mammotome
At Mammotome, our expertise and compassion for breast care makes us the indispensable partner to physicians, clinicians and patients. Our drive for innovation is rivaled only by our compassion for the people we serve, from the clinicians and surgeons who demand consistently precise solutions, to the patients and families seeking peace of mind. Headquartered in Cincinnati, OH, Mammotome is proud to be a part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. The Mammotome brand of products is sold in over 65 different countries throughout the world.
About Sirius Medical
With its roots deeply embedded in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivering unsurpassed yet affordable solutions that enable precise and efficient removal of tumors. The Pintuition® technology is simple, precise, affordable, CE-marked, and FDA-cleared. Sirius Medical is rapidly expanding with over 50,000 procedures worldwide in more than 250 centers and a global commercial network covering the United States, Europe, Australia, and New Zealand.
Media Contact:
Erica Bednar
Marketing Communications Director
Mammotome
+1 513-391-4737
Erica.Bednar@Mammotome.com
Benjamin Tchang
Marketing Director
Sirius Medical
+31 647 852 805
Benjamin.tchang@sirius-medical.com